AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference
CASTLE ROCK, CO--(Marketwire - November 13, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an
emerging bio-science company dedicated to the development of novel
diagnostics and drugs for humans and animals, has been invited to present
at the Lazard Capital Market 6th Annual Healthcare Conference to be held
November 17-18, 2009 at The St. Regis Hotel New York, NY.
Company management is scheduled to present on Tuesday, November 17, 2009 at
9:25 a.m. Eastern time, with one-on-one meetings held throughout the day.
Management will discuss the company's progress, including its recently
filed Premarket Notification 510(k) with the U.S. Food and Drug
Administration for AppyScore™, the first blood-based test designed to
aid in the diagnosing or ruling out human appendicitis.
AspenBio is also advancing a new class of drugs that replace natural
reproductive hormones for animals of economic importance. The company has a
development and marketing agreement with Novartis Animal Health (NYSE: NVS)
for the bovine species.
Leading the presentation will be the company's executive chairman and CEO,
Daryl Faulkner, who was previously president, CEO and board member of
Digene Corp., a Nasdaq-traded company prior to its acquisition by Qiagen.
For more information, please visit the conference website at
http://www.lazardcap.com/conferenceList.aspx?tn=4&ln=3&itm=2123&lid=758 or
contact the 2009 Healthcare Conference event team at
HealthcareConference@lazardcap.com.
About AspenBio Pharma, Inc.
AspenBio Pharma's mission is to be a leader in the development and
commercialization of innovative products that address unmet diagnostic and
therapeutic needs in both Human and Animal Health. Our Human Health
Division is addressing the difficult challenge of diagnosing appendicitis
in the hospital emergency department setting. Our Animal Health Division is
focused on therapeutic proteins that support reproductive efficiency in
animals of economic importance. For more information, go to
http://www.aspenbiopharma.com.
About Lazard Capital Markets
Lazard Capital Markets LLC was formed in 2005 concurrent with the
recapitalization of Lazard Group LLC and initial public offering of Lazard
Ltd. Headquartered in New York's Rockefeller Center, we continue all of the
capital markets activities formerly conducted by Lazard Frères & Co. LLC.
Lazard Frères & Co. LLC, one of the world's preeminent financial advisory
and asset management firms, operates from 39 cities across 21 countries in
North America, Europe, Australia, Asia and South America. With origins
dating back to 1848, the firm provides advice on mergers and acquisitions,
restructuring and capital raising, as well as asset management services, to
corporations, partnerships, institutions, governments and individuals.